HOME >> MEDICINE >> NEWS
New studies show mixed results on epilepsy drugs and birth defects

e pregnancy occurs."

The bad news is about the drug valproic acid. One study monitored the rate of birth defects in infants whose mothers had taken valproic acid as their only epilepsy drug during the first trimester of pregnancy and were enrolled in the North American Antiepileptic Drug (AED) Pregnancy Registry. Of the 149 women in the study, there were 16 infants with birth defects, or 10.7 percent. The women taking valproic acid were nearly three times more likely to have an infant with a birth defect than women taking another epilepsy drug. They were more than seven times more likely to have an infant with a birth defect than women in the general population.

For the second study on valproic acid, British researchers recruited 163 mothers with epilepsy and their children and gave them a number of tests. A total of 249 children between the ages of 6 and 16 took the tests. The 41 children who were exposed to valproic acid during pregnancy were more likely to have low verbal IQ scores (average of 84) compared to other groups in the study, such as those exposed only to the drug phenytoin (average score of 99) or those not exposed to any epilepsy drug during pregnancy (average score of 92).

Those exposed to valproic acid were also more likely to have overall IQ scores in the extremely low, or mentally impaired, range. Two to three percent of the population would be expected to fall in this range. In the study, 22 percent of those exposed to valproic acid were in this range.

Penovich noted that maintaining effective epilepsy treatment during pregnancy is crucial. "Seizures can cause fetal distress, and the severe epilepsy state called status epilepticus where attacks occur in rapid succession may cause catastrophic damage to the brain of the fetus," she said. More studies must be done to understand how valproic acid works to affect fetal development. "Without good animal models, the mechanism for the abnormalities remains unknown," Penov
'"/>

Contact: Marilee Reu
mreu@aan.com
651-695-2789
American Academy of Neurology
21-Mar-2005


Page: 1 2 3

Related medicine news :

1. New studies suggest airborne SARS transmission is possible
2. Brain imaging studies investigate pain reduction by hypnosis
3. Impact of scientific advances on drug studies and membrane research to be explored
4. Two studies find evidence that sunlight may have beneficial influence on cancer
5. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
6. Animal studies show stem cells might make biological pacemaker
7. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find
8. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
9. Gender and sex hormones affect the brains pain response and more, according to new studies
10. Analysis of tamoxifen studies reveals slight increase of stroke risk
11. Imaging studies clarify brain changes associated with language deficits in autism

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New studies show mixed results epilepsy drugs and birth defects

(Date:8/4/2015)... ... August 05, 2015 , ... Renowned review site BestMillionaireDatingSites.com recently refreshed ... update, MillionaireMatch.com has been ranked as the best dating service in the segment. , ... life companion. It is essential that people find the right dating platform so that ...
(Date:8/4/2015)... ... ... How cool is it to check in at your favorite place and be ... soon allow you to do just that. , Ahhaa is releasing the next version ... , Users will soon get to share what inspires them about their favorite places ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sponsored by Gila River Casinos, the charity ... 501(c) nonprofit organization. , According to the New Foundation AZ spokesperson , the ... package that includes a complimentary foursome for the tournament, as well as getting their ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... technology platform that uses Cloud innovation to consolidate oncology patient assistance programs. Through ... a single point of access. assistPoint is an enterprise level, cloud-based application and ...
(Date:8/4/2015)... ... ... Rhode Island Medical Imaging (RIMI) is pleased to announce the opening of ... Road in Lincoln, RI. This satellite office will provide x-ray and ultrasound exams. ... hours in the state, which includes evenings and weekends. , “This satellite office ...
Breaking Medicine News(10 mins):Health News:BestMillionaireDatingSites.com Publishes Reviews of the Best Dating Sites for Wealthy Singles 2Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:The New Foundation AZ to Host Charity Golf Tournament 2Health News:The New Foundation AZ to Host Charity Golf Tournament 3Health News:assistPoint.com Web Site Launched 2Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2
(Date:8/4/2015)... SOUTHAMPTON , England ... Ltd (ASX: PXS) and UK biotechnology company Synairgen plc (LSE: ... to develop a selective inhibitor to the lysyl oxidase type ... pulmonary fibrosis (IPF). IPF affects in the ... expected to produce global revenues in excess of $1.1 billion ...
(Date:8/4/2015)... -- On August 3, 2015, a press conference on anti-virus ... donation ceremony of a million masks by Wuhan Longfeixiang Technology ... . Wuhan Longfeixiang Technology ... Hubei Longfeixiang Industrial Group, which has successfully developed the ... anti-pollution mask, filling the global gap for masks of ...
(Date:8/4/2015)... ALGONQUIN, Ill. , Aug. 4, 2015 /PRNewswire/ ... of dental supplies and equipment, today announced the ... of Medical Products Laboratories, Inc. ("MPL PDCMD"). MPL ... materials used in preventive and restorative dental procedures. ... strategic expansion of our business in attractive, high-growth ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2
Cached News: